Ilyang Pharmaceutical company completed patient enrollment in Phase III clinical trial of Suepect
On Feb 26, Ilyang Pharmaceutical company (CEO Kim, Dong-Youn) announced that they has completed patient enrollment in Phase III clinical trials of leukemia treatment 'Supect (ingredient: radotinib)' for its entry into the first line treatment.
'Supect' has proceeded with Phase III clinical tri...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
